Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Posts Earnings Results, Misses Estimates By $0.05 EPS

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) issued its quarterly earnings results on Thursday. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05), Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.32% and a net margin of 37.95%. The company had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.11 billion.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shares of SGIOY stock traded up $0.08 on Friday, hitting $9.52. 49,885 shares of the stock were exchanged, compared to its average volume of 95,052. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $8.11 and a one year high of $12.00. The firm’s 50 day moving average is $9.18 and its two-hundred day moving average is $9.64. The firm has a market capitalization of $16.20 billion, a PE ratio of 10.58, a P/E/G ratio of 3.39 and a beta of 0.08. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

SGIOY has been the topic of several research reports. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three equities research analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.